Novavax Inc
NVAXHealthcare|Biotechnology|USA
$9.33
-0.07 (-0.74%)
Earnings Power
$97.87
Clinical Trials (53)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07086222 Efficacy and Safety of NVX-CoV2705 | COVID-19, Sars-CoV-2 Infection | P4 | Active | 6,500 | RCT, Double-blind | NVX-CoV2705, Placebo |
| NCT06065176 The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection | COVID-19, Vaccine-Preventable Diseases | P4 | Completed | 1,188 | RCT, Double-blind | Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) |
| NCT06633835 Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | COVID-19, Vaccine-Preventable Diseases | P4 | Completed | 660 | Open-label | protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine |
| NCT04583995 A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom | SARS-CoV-2 Infection, COVID-19 | P3 | Completed | 15,185 | RCT, Double-blind | SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine |
| NCT04120194 Phase 3 Pivotal Trial of NanoFlu™ in Older Adults | Influenza, Human | P3 | Completed | 2,654 | RCT, Double-blind | NanoFlu, Fluzone Quadrivalent |
| NCT06482359 Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | COVID-19, Influenza | P2P3 | Withdrawn | — | RCT, Single-blind | coformulated CIC Vaccine, Fluzone HD trivalent |
| NCT05925127 Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | COVID-19 | P2P3 | Completed | 994 | RCT, Double-blind | NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5 |
| NCT07079670 Safety and Immunogenicity of NVX-CoV2705 | COVID-19, SARS-CoV-2 Infection | P3 | Completed | 676 | Open-label | NVX-CoV2705 |
| NCT06485752 Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | COVID-19 | P2P3 | Withdrawn | — | RCT, Single-blind | tNIV 1 and Matrix-M Adjuvant |
| NCT05975060 A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. | COVID-19 | P2P3 | Completed | 660 | RCT, Open-label | XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose) |
| NCT05973006 Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | COVID-19 | P3 | Completed | 400 | RCT, Double-blind | NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg) |
| NCT06409663 A Strain Change Study for SARS-CoV-2 rS Vaccines | Severe Acute Respiratory Syndrome Coronavirus 2 Infection | P3 | Completed | 60 | Open-label | NVX-CoV2705 Vaccine |
| NCT05875701 Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines | COVID-19 | P3 | Completed | 147 | RCT, Open-label | NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant |
| NCT05372588 Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines | COVID-19, SARS CoV 2 Infection | P3 | Completed | 1,340 | RCT, Double-blind | NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515, NVX-CoV2540, NVX-CoV2373 + NVX-CoV2540 |
| NCT04611802 A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | SARS-CoV Infection, Covid19 | P3 | Completed | 33,000 | RCT, Double-blind | SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination) |
| NCT05249816 Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | P3 | Completed | 1,000 | RCT, Double-blind | NVX-CoV2373, BBIBP-CorV vaccine |
| NCT02608502 A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults | Respiratory Syncytial Virus (RSV) | P3 | Completed | 11,850 | RCT, Double-blind | RSV-F Vaccine, Phosphate Buffer Placebo |
| NCT05468736 Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years | COVID-19 | P2P3 | Completed | 3,600 | RCT, Double-blind | SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) |
| NCT06291857 A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | COVID-19 | P3 | Completed | 9,320 | RCT, Single-blind | CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine, Fluzone High Dose |
| NCT05463068 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | COVID-19, SARS-CoV-2 Infection | P3 | Completed | 911 | RCT, Double-blind | NVX-Cov2373 |
| NCT02624947 A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization | Respiratory Syncytial Virus Infections | P3 | Completed | 4,636 | RCT, Double-blind | RSV F vaccine with adjuvant, Formulation buffer |
| NCT00903552 Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) | Seasonal Influenza | P2 | Completed | 221 | RCT, Double-blind | Influenza VLP Vaccine, Placebo |
| NCT01014806 Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults | Influenza | P2 | Completed | 467 | RCT, Double-blind | Influenza VLP Vaccine, TIV |
| NCT02266628 Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults | Respiratory Syncytial Virus (RSV) | P2 | Completed | 1,599 | RCT, Double-blind | RSV-F Vaccine, Saline Placebo |
| NCT02078674 A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant | Influenza (Pandemic) | P1P2 | Completed | 610 | RCT, Double-blind | Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo |
| NCT03293498 Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) | Influenza | P1P2 | Completed | 330 | RCT, Double-blind | NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21 |
| NCT02247726 RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. | Respiratory Syncytial Virus Infections | P2 | Completed | 50 | RCT, Double-blind | Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection) |
| NCT03026348 Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults | Respiratory Syncytial Viruses | P2 | Completed | 300 | RCT, Double-blind | RSV F Vaccine with Aluminum Phosphate Adjuvant, RSV F Vaccine, Matrix-M1 Adjuvant |
| NCT00754455 Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults | Influenza | P2 | Completed | 317 | RCT, Double-blind | Influenza VLP Vaccine (recombinant), Placebo |
| NCT04533399 A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults | SARS-CoV-2 Infection, COVID-19 | P2 | Completed | 4,422 | RCT, Double-blind | SARS-CoV-2 rS/Matrix-M1 Adjuvant |
| NCT02593071 Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. | Respiratory Syncytial Virus (RSV) | P2 | Completed | 1,330 | RCT, Double-blind | RSV-F Vaccine, Phosphate Buffer Placebo |
| NCT03658629 Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults | Influenza, Human | P2 | Terminated | 1,375 | RCT, Double-blind | NanoFlu (Quad-NIV), Fluzone HD, Flublok Quadrivalent, Influenza Vaccine |
| NCT01704365 RSV-F Vaccine Dose Ranging Study in Young Women | Respiratory Syncytial Virus (RSV) | P2 | Completed | 330 | RCT, Double-blind | Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo |
| NCT04961541 Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine | SARS-CoV Infection, Covid19 | P1P2 | Completed | 637 | RCT, Double-blind | ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant |
| NCT01960686 RSV F Dose-Ranging Study in Women | Respiratory Syncytial Virus Infections | P2 | Completed | 720 | RCT, Double-blind | Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo |
| NCT06027229 Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations | Immunosuppression, COVID-19 | P2 | Completed | 21 | Open-label | NVX-CoV2372 |
| NCT01561768 A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults | Influenza | P2 | Completed | 500 | RCT, Double-blind | Novavax Quadrivalent vaccine, Novavax Quadrivalent vaccine, Novavax Quadrivalent vaccine, Novavax Trivalent vaccine, cTIV |
| NCT05519839 A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine | COVID-19, Influenza | P2 | Completed | 1,579 | RCT, Double-blind | qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant, SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant |
| NCT01072799 Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine | Seasonal Influenza | P2 | Completed | 4,560 | RCT, Double-blind | Placebo, A/H1N1 2009 Influenza VLP Vaccine |
| NCT00519389 Safety, Reactogenicity and Immunogenicity of an H5N1 VLP | Pandemic Influenza | P1P2 | Completed | 230 | RCT, Double-blind | H5N1 VLP Vaccine, Placebo |
| NCT02307851 Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults | Influenza | P2 | Completed | 400 | RCT, Double-blind | Quadrivalent VLP Vaccine, Comparator TIV |
| NCT05112848 A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) | SARS-CoV-2 Infection | P2 | Completed | 384 | RCT, Double-blind | NVX-CoV2373 |
| NCT05029856 Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults | Covid19 | P1P2 | Withdrawn | — | RCT, Double-blind | SII B.1.351, SII B.1.351, SII Bivalent, SII Bivalent, SII B.1.617.2 |
| NCT04368988 Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | COVID-19 | P1P2 | Completed | 1,419 | RCT, Double-blind | SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 |
| NCT05135273 Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali | Malaria,Falciparum | P1 | Completed | 80 | RCT, Double-blind | Pfs230D1-EPA/Matrix-M Vaccine, Verorab Rabies Vaccine |
| NCT01596725 A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2 | Influenza (Pandemic) | P1 | Completed | 333 | RCT, Double-blind | Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo |
| NCT01290419 Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine | Respiratory Syncytial Virus Infections | P1 | Completed | 150 | RCT, Double-blind | RSV-F Particle Vaccine, RSV-F Particle Vaccine, RSV-F Particle Vaccine, RSV-F Particle Vaccine, Placebo, RSV-F Particle Vaccine, RSV-F Particle Vaccine |
| NCT02370589 Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects | Ebola | P1 | Completed | 230 | RCT, Double-blind | Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine, 4x Base Dose EBOV GP Vaccine, 8x Base Dose EBOV GP Vaccine, Placebo, Matrix-M Adjuvant |
| NCT01594320 A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1 | Influenza (Pandemic) | P1 | Completed | 333 | RCT, Double-blind | Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo |
| NCT01709019 RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly | Respiratory Syncytial Virus (RSV) | P1 | Completed | 220 | RCT, Double-blind | Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0) |
| NCT01897701 A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 | Avian Influenza | P1 | Completed | 280 | RCT, Double-blind | Monovalent Avian Influenza VLP (H7N9), Adjuvant 1, Placebo |
| NCT02296463 A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age | Respiratory Synctial Virus | P1 | Completed | 32 | RCT, Double-blind | RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccine (0.5mL injection), Hepatitis A Vaccine (0.5mL injection), Placebo (0.5mL injection) |
| NCT04862416 Safety and Efficacy of R0.6C Vaccine | Malaria, Malaria,Falciparum | P1 | Completed | 32 | RCT, Open-label | R0.6C transmission blocking vaccine |